Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Mid-Atlantic BioTherapeutics Inks Deal with Wunderkind™ to Deploy Viral Outbreak Warning System (VOWS™) - Venture Promises Rapid Deployment of COVID-19 Toolset

Mid-Atlantic BioTherapeutics (MABT) has engaged with New York-based technology firm Wunderkind, LLC to develop and deploy the Viral Outbreak Warning System (VOWS™) platform. VOWS™ is an artificial intelligence/machine learning (AI/ML)-driven technology system that will analyze a broad set of both public and private data in order to accurately identify viral infection hot zones and predict future outbreaks.


News provided by

Wunderkind, LLC

Jun 22, 2020, 09:30 ET

Share this article

Share toX

Share this article

Share toX


NEW YORK, June 22, 2020 /PRNewswire-PRWeb/ -- Mid-Atlantic BioTherapeutics (MABT) has engaged with New York-based technology firm Wunderkind, LLC to develop and deploy the Viral Outbreak Warning System (VOWS™) platform. VOWS™ is an artificial intelligence/machine learning (AI/ML)-driven technology system that will analyze a broad set of both public and private data in order to accurately identify viral infection hot zones and predict future outbreaks.

As all are now aware, viral pandemics represent a catastrophic medical, societal, and economic burden to humanity. Health security stakeholders such as healthcare systems, local and federal health agencies, insurance companies and NGOs have an urgent need for predictive algorithms that can better monitor potential viral outbreaks in order to mobilize effective prevention and treatment countermeasures.

Wunderkind has both deep experience in health technology, as well as expertise in leveraging AI to perform real-time identity resolution and infer patterns from deep and disparate datasets such as anonymous social media actions.

Post this

There is an urgent global need right now for enhanced predictive surveillance. Resurgence of SARS-CoV-2/COVID-19 transmission is already evident as societies reopen, thus highlighting the value of implementing the VOWS™ platform as soon as possible to identify hot zones as they occur.

In order to meet this need, MABT and Wunderkind™ expect that the first working prototype of the VOWS™ platform will be available by late 2020.

VOWS™ will continuously ingest huge amounts of data from a diverse set of sources such as CDC, ClinicalTrials.gov, hospitals, insurance companies, pharmacies, PubMed, and social networks such as Facebook, Twitter, Instagram, etc. Where required, the data will be anonymized and protected utilizing trustless decentralized blockchain strategies.

Then, VOWS's proprietary AI analysis and interactive visualization tools will identify and correlate critical 'cause and effect' relationships between previously unconnected variables leading to disease and outbreak trends.

Although the current focus is addressing the essential needs of the moment, the VOWS™ platform has applications beyond the current pandemic. It will also be useful for surveilling influenza and other infectious diseases (e.g., Ebola, Marburg), future novel virus outbreaks, and even opioid-related events.

There is considerable excitement about VOWS's potential as a disease surveillance game-changer. Mid-Atlantic BioTherapeutics has received interest from a range of government and industry organizations looking to support the development and deployment of the VOWS™ technology.

Tammo Mueller, Co-Founder & CEO of Wunderkind, LLC commented, "We are very excited to work with Mid-Atlantic BioTherapeutics on VOWS™. As everyone is aware now, the potential benefits to identifying viral infection hot zones, and predicting future outbreaks cannot be overstated. We believe that our expertise in AI and Blockchain will allow us to rapidly deliver a first iteration of the platform."

David Jobes, Ph.D., Co-Founder & President of Mid-Atlantic BioTherapeutics noted that "It didn't take long for us to realize that Wunderkind was the right choice to be our VOWS™ technology partner. Not only do they have deep experience in various aspects of health technology, their expertise also includes leveraging AI to perform real-time identity resolution and infer patterns from deep and disparate datasets such as anonymous social media actions. They have the toolbox we needed."

About Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics (http://mabt.us) was founded in 2011 with the mission of eradicating infectious diseases. MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of novel anti-infective approaches such as the patented IMT504 technology platform that harnesses the body's own immune response to fight off infections. The company is actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases, emerging infectious diseases and biodefense.

About Wunderkind™
Wunderkind™ (http://wunderkind.nyc) is a boutique technology consultancy and product studio that provides guidance and collaboration from the formulation of business and product strategies all the way to final implementation for a diverse set of clients in healthcare, data-driven marketing, commerce, finance, and digital transformation & AI. Wunderkind™ creates near- and long-term strategies for clients to stay ahead of marketplace disruption through the design and deployment of innovative solutions that utilize emerging technologies such as AI and blockchain.

SOURCE Wunderkind, LLC

Related Links

http://wunderkind.nyc

Modal title

Wunderkind, LLC
Wunderkind, LLC
Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics
Viral Outbreak Warning System (VOWS™)
View PDF
Viral Outbreak Warning System (VOWS™)
Wunderkind, LLC
Wunderkind, LLC
Wunderkind, LLC Mid-Atlantic BioTherapeutics Viral Outbreak Warning System (VOWS™) Wunderkind, LLC

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.